Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding Ltd (OP:RHHVF)

421.51 +1.51 (+0.36%)

Streaming Delayed Price Updated: 3:53 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Ltd

< Previous 1 2 3 4 5 6 7 Next >

EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody ↗

April 13, 2023

The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...

Via Benzinga

New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients ↗

March 20, 2023

Via Benzinga

FDA Casts Doubts Over Roche's Polivy Label Expansion For Untreated Lymphoma Setting ↗

March 09, 2023

Via Benzinga

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗

March 03, 2023

Via Benzinga

Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines ↗

February 23, 2023

Via Benzinga

New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder ↗

February 10, 2023

Via Benzinga

Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition ↗

February 07, 2023

Via Benzinga

Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics ↗

February 02, 2023

Via Benzinga

Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer ↗

January 19, 2023

Via Benzinga

Europe Approves Xofluza, Roche's Revolutionary Influenza Antiviral with New Mechanism ↗

January 12, 2023

Via Benzinga

Roche's Investigational Lymphoma Candidate Goes Under FDA Priority Review ↗

January 06, 2023

Via Benzinga

Roche's Follicular Lymphoma Therapy Scores FDA Approval ↗

December 23, 2022

Via Benzinga

FDA Approves Roche's Tocilizumab As First Monoclonal Antibody For COVID-19 Treatment ↗

December 22, 2022

Via Benzinga

Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates ↗

December 12, 2022

Via Benzinga

After 16 Years, Roche's Pharma Division Head Decides To Step Down ↗

December 12, 2022

Via Benzinga

Replimune Shares Surge After Early Data From Pretreated Melanoma Patients ↗

December 07, 2022

Via Benzinga

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Gives Emergency Use Nod To Roche's Monkeypox Test ↗

November 16, 2022

Via Benzinga

Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗

November 15, 2022

Via Benzinga

Roche Inks Second Drug Discovery Deal With Jnana Therapeutics ↗

November 15, 2022

Via Benzinga

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗

November 14, 2022

Via Benzinga

Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months ↗

November 14, 2022

Via Benzinga

Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide ↗

October 18, 2022

Via Benzinga

Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients ↗

October 12, 2022

Via Benzinga

Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests ↗

October 12, 2022

Via Benzinga

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility ↗

October 03, 2022

Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California.

Via Benzinga

FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗

September 27, 2022

Via Benzinga

COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗

September 23, 2022

The World Health Organization (WHO) warned that it struggles to identify and

Via Benzinga

Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders ↗

September 19, 2022

Via Benzinga

WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗

September 16, 2022

Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Roche Holding Ltd (OP:RHHVF)

All News about Roche Holding Ltd

Starting at $3.75/week.

Subscribe Today